A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Lupus Nephritis

In brief

The purpose of this study was to assess the efficacy and safety of zetomipzomib (30 mg or 60 mg) compared with placebo in achieving renal response after 52 weeks of treatment in patients with active lupus nephritis (LN).

Key facts

Study ID
NCT05781750
Run by
Kezar Life Sciences, Inc.
People needed
84
Starts
2023-11-03
Expected to finish
2024-11-08
Last updated by the study team
2025-12-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.